Xiaoqing Yu
Chinese Academy of Sciences
CorrelationMutation (genetic algorithm)Copy-number variationInternal medicineOncologyCD8ImmunohistochemistryT cellTumor microenvironmentLung cancerChemotherapyPerformance statusCombination therapyVascular endothelial growth factorOsimertinibImmunotherapyT790MBrain metastasisnon-small cell lung cancer (NSCLC)CrizotinibEpidermal growth factor receptorCDKN2APD-L1KRASEGFR T790MNon small cellMet amplificationImmune checkpoint inhibitorsCancer researchMedicineCohortAbundance (ecology)ComplicationImmune system
6Publications
2H-index
11Citations
Publications 7
Newest
#1Jiamin Sheng (WMU: Wenzhou Medical College)
#2Hui Li (CAS: Chinese Academy of Sciences)H-Index: 1
Last. Yun Fan (CAS: Chinese Academy of Sciences)H-Index: 3
view all 10 authors...
Background null There is only limited knowledge of the treatment responses and clinical outcomes of immune checkpoint inhibitors (ICIs) in driver gene-negative non-small cell lung cancer (NSCLC) patients with brain metastases (BM). This study aims to assess the efficacy of immunotherapy in these patients in a real world setting. null Methods null NSCLC-BM patients without driver gene mutations who received ICIs were retrospectively identified between July 2017 and December 2019. The primary obse...
Source
#1Xiaoqing Yu (CAS: Chinese Academy of Sciences)H-Index: 2
#2Jiamin Sheng (CAS: Chinese Academy of Sciences)H-Index: 1
Last. Yun Fan (CAS: Chinese Academy of Sciences)H-Index: 3
view all 4 authors...
Brain metastases (BMs) cause morbidity and mortality in patients with non-small cell lung cancer (NSCLC). The optimal management of epidermal growth factor receptor (EGFR)-mutated NSCLC with BM is debatable. We aimed to investigate the impact of different treatments among patients with EGFR-mutated NSCLC. A cohort of 2058 lung cancer patients with BM between 2013 and 2018 was retrospectively studied. A total of 571 patients with EGFR-mutated NSCLC and BM were enrolled. All patients had received ...
Source
Source
#1Kaiyan Chen (CAS: Chinese Academy of Sciences)H-Index: 11
#2Fanrong Zhang (CAS: Chinese Academy of Sciences)H-Index: 8
Last. Yun Fan (CAS: Chinese Academy of Sciences)H-Index: 2
view all 9 authors...
Source
#1Yanjun Xu (CAS: Chinese Academy of Sciences)H-Index: 7
#2Hui LiH-Index: 1
Last. Yun Fan (WMU: Wenzhou Medical College)H-Index: 4
view all 8 authors...
Background Immune checkpoint inhibitors (ICIs) prolong overall survival (OS) in patients with advanced lung squamous cell carcinoma (LUSC). However, predictive and prognostic factors related to ICIs in LUSC remain elusive. This study aimed to identify predictors that are related to better clinical benefit and outcomes in LUSC patients treated with immunotherapy. Methods Capture-based targeted sequencing was performed in 64 patients with advanced LUSC who underwent immunotherapy. Tumor mutational...
5 CitationsSource
#1Jiamin Sheng (WMU: Wenzhou Medical College)
#2Xiaoqing Yu (CAS: Chinese Academy of Sciences)H-Index: 2
Last. Yun Fan (CAS: Chinese Academy of Sciences)
view all 4 authors...
Brain metastasis (BM) is a common complication in non-small cell lung cancer (NSCLC), which associates with poor prognosis. Recently, immune checkpoint inhibitors (ICIs) has revolutionized the treatment of tumors. Programmed death-1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors could produce antitumor effect by activating the autoimmune system. The immunotherapy has already show to have a promising outcome for NSCLC patients with BM, while its specific curative effect and the most ideal mo...
Source
#1Kaiyan Chen (CAS: Chinese Academy of Sciences)H-Index: 11
#2Guoping Cheng (CAS: Chinese Academy of Sciences)H-Index: 6
Last. Yun Fan (CAS: Chinese Academy of Sciences)H-Index: 2
view all 8 authors...
Abstract Objectives The efficacy of immunotherapy in epidermal growth factor receptor (EGFR)-activating non-small cell lung cancer (NSCLC) is limited. However, a series of patients with uncommon EGFR alterations was reported to derive clinical benefit from PD-1 blockade. To characterize the tumor immune microenvironment, we retrospectively evaluated tumor PD-L1 expression and T cells infiltration among NSCLC patients with uncommon EGFR mutations. Materials and methods Immunohistochemistry was us...
13 CitationsSource